152 related articles for article (PubMed ID: 37198599)
1. Early access programs for medicines: comparative analysis among France, Italy, Spain, and UK and focus on the Italian case.
Tarantola A; Otto MH; Armeni P; Costa F; Malandrini F; Jommi C
J Pharm Policy Pract; 2023 May; 16(1):67. PubMed ID: 37198599
[TBL] [Abstract][Full Text] [Related]
2. Differences in time to patient access to innovative cancer medicines in six European countries.
Vancoppenolle JM; Franzen N; Koole SN; Retèl VP; van Harten WH
Int J Cancer; 2024 Mar; 154(5):886-894. PubMed ID: 37864395
[TBL] [Abstract][Full Text] [Related]
3. Expanded Access Programme: looking for a common definition.
Iudicello A; Alberghini L; Benini G; Mosconi P
Trials; 2016 Jan; 17():21. PubMed ID: 26758369
[TBL] [Abstract][Full Text] [Related]
4. How to anticipate the assessment of the public health benefit of new medicines?
Massol J; Puech A; Boissel JP;
Therapie; 2007; 62(5):427-35. PubMed ID: 18206104
[TBL] [Abstract][Full Text] [Related]
5. The economic impact of compassionate use of medicines.
Jommi C; Pantellini F; Stagi L; Verykiou M; Cavazza M
BMC Health Serv Res; 2021 Dec; 21(1):1303. PubMed ID: 34863155
[TBL] [Abstract][Full Text] [Related]
6. Comparing access to orphan medicinal products in Europe.
Zamora B; Maignen F; O'Neill P; Mestre-Ferrandiz J; Garau M
Orphanet J Rare Dis; 2019 May; 14(1):95. PubMed ID: 31053154
[TBL] [Abstract][Full Text] [Related]
7. Comparing patient access to pharmaceuticals in the UK and US.
Cohen J; Cairns C; Paquette C; Faden L
Appl Health Econ Health Policy; 2006; 5(3):177-87. PubMed ID: 17132032
[TBL] [Abstract][Full Text] [Related]
8. Methods for the comparative evaluation of pharmaceuticals.
Zentner A; Velasco-Garrido M; Busse R
GMS Health Technol Assess; 2005 Nov; 1():Doc09. PubMed ID: 21289930
[TBL] [Abstract][Full Text] [Related]
9. [Cost-effectiveness analysis of schizophrenic patient care settings: impact of an atypical antipsychotic under long-acting injection formulation].
Llorca PM; Miadi-Fargier H; Lançon C; Jasso Mosqueda G; Casadebaig F; Philippe A; Guillon P; Mehnert A; Omnès LF; Chicoye A; Durand-Zaleski I
Encephale; 2005; 31(2):235-46. PubMed ID: 15959450
[TBL] [Abstract][Full Text] [Related]
10. Access to medicines for rare diseases: A European regulatory roadmap for academia.
Rosenberg N; van den Berg S; Stolwijk NN; Jacobs BAW; Post HC; Pasmooij AMG; de Visser SJ; Hollak CEM
Front Pharmacol; 2023; 14():1142351. PubMed ID: 36925633
[No Abstract] [Full Text] [Related]
11. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
12. Reimbursement of Orphan Drugs in Europe in Relation to the Type of Authorization by the European Medicines Agency and the Decision Making Based on Health Technology Assessment.
Malinowski KP; Kawalec P; Trabka W; Sowada C; Pilc A
Front Pharmacol; 2018; 9():1263. PubMed ID: 30483124
[No Abstract] [Full Text] [Related]
13. Access and use of WHO essential medicines in Italy.
Petrella A; Fortinguerra F; Cangini A; Pierantozzi A; Trotta F
Front Public Health; 2023; 11():1211208. PubMed ID: 37881343
[TBL] [Abstract][Full Text] [Related]
14. Temporary authorization for use: does the French patient access programme for unlicensed medicines impact market access after formal licensing?
Degrassat-Théas A; Paubel P; Parent de Curzon O; Le Pen C; Sinègre M
Pharmacoeconomics; 2013 Apr; 31(4):335-43. PubMed ID: 23529210
[TBL] [Abstract][Full Text] [Related]
15. [Early access programs and managed entry agreements for medicines in Italy: results of a Focus Group (Early Access Programs and Managed Entry Agreement).].
Jommi C; Armeni P; Costa F; Alberti C; Bandello F; Bordonaro R; Caprodossi A; Di Maio M; Gaudioso A; Giuliani G; Langella R; Marata AM; Patarnello F; Pinto C; Rasi G; Villa F
Recenti Prog Med; 2021 Nov; 112(11):749-756. PubMed ID: 34782810
[TBL] [Abstract][Full Text] [Related]
16. Use and reimbursement of off-label drugs in pediatric anesthesia: the Italian experience.
Salvo I; Landoni G; Mucchetti M; Cabrini L; Pani L
Paediatr Anaesth; 2014 Jun; 24(6):625-31. PubMed ID: 24796404
[TBL] [Abstract][Full Text] [Related]
17. Global spending on orphan drugs in France, Germany, the UK, Italy and Spain during 2007.
Orofino J; Soto J; Casado MA; Oyagüez I
Appl Health Econ Health Policy; 2010; 8(5):301-15. PubMed ID: 20804223
[TBL] [Abstract][Full Text] [Related]
18. [Reform of early access program in France: Impact on workload in a pharmacy and risk identification].
Jouhet O; Demir J; Sitbon M; Bildan MA; Bros A; Kim E; Godron N; Madelaine I; Deville L
Ann Pharm Fr; 2024 Jun; 82(4):727-738. PubMed ID: 38408723
[TBL] [Abstract][Full Text] [Related]
19. Access to innovation through the national early access program and clinical trials for patients with malignant melanoma.
Christen C; Belgodère L; Guillot B; Jumeau C; Lorence A; Kerouani-Lafaye G; Brunel L; Turcry F; Monard A; Grudé F; Guyader G; Boudali L; Albin N
Cancer; 2021 Jul; 127(13):2262-2270. PubMed ID: 33764524
[TBL] [Abstract][Full Text] [Related]
20. Self-monitoring of blood glucose (SMBG) in patients with type 2 diabetes on oral anti-diabetes drugs: cost-effectiveness in France, Germany, Italy, and Spain.
Tunis SL; Willis WD; Foos V
Curr Med Res Opin; 2010 Jan; 26(1):163-75. PubMed ID: 19919377
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
